68
Views
1
CrossRef citations to date
0
Altmetric
Review

Subclinical hypothyroidism and subclinical hyperthyroidism

Pages 359-373 | Published online: 10 Jan 2014
 

Abstract

Subclinical thyroid dysfunction occurs when peripheral thyroid hormone levels are within the normal laboratory reference range and the serum thyroid-stimulating hormone (TSH or thyrotropin) level is greater than normal (subclinical hypothyroidism) or less than normal (subclinical hyperthyroidism; TSH normal laboratory reference range: 0.3–5.0 mIU/l). For patients with subclinical hypothyroidism (serum TSH levels >10 mIU/l), thyroxine therapy is prescribed if other causes of TSH elevation and transient conditions have been excluded. For serum TSH levels between 5.0 and 10.0 mIU/l, selective therapy should be considered. For patients with sustained subclinical hyperthyroidism (serum TSH levels <0.1 mIU/l), therapy is recommended, especially in older patients. Observation or selective therapy should be considered for patients with serum TSH levels between 0.1 and 0.3 mIU/l.

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Notes

TSH: Thyroid-stimulating hormone.

Data from Citation[17–19].

AACE: American Association of Clinical Endocrinologists; NACB: National Academy of Clinical Biochemistry; NHANES: National Health and Nutrition Examination Survey.

TSH: Thyroid-stimulating hormone.

TSH: Thyroid-stimulating hormone.

Modified from Citation[31].

TSH levels higher than 8.0 mIU/l increase the likelihood of progression to TSH higher than 10.0 mIU/l in 3 years [Fatourechi et al., unpublished data (2003)].

Down syndrome patients are at high risk of progression to overt hypothyroidism.

TSH: Thyroid-stimulating hormone.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.